Shabir A. Madhi
Elite in Streptococcal Group B Infection

Shabir A. Madhi

Johannesburg, GT, ZA 
Elite in Streptococcal Group B Infection
Johannesburg, GT, ZA 
OverviewLocationsClinical Research

Overview

Shabir Madhi practices in Johannesburg, South Africa. Mr. Madhi is rated as an Elite expert by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Streptococcal Group B Infection, Strep Throat, Parainfluenza, and Neonatal Sepsis.

His clinical research consists of co-authoring 644 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 74 articles and participated in 2 clinical trials in the study of Streptococcal Group B Infection.

Gender
Male

Locations

Johannesburg, GT, South Africa
Other Locations
University Of Cape Town, Cape Town, WC, South Africa
Parktown, GT, South Africa
South Africa, WC, South Africa
University Of Cape Town, Cape Town, Stellenbosch, WC, South Africa
South Africa
University Of Cape Town, Cape Town, Centurion, GT, South Africa
St John Eye Hospital, Soweto, GT, South Africa
St John Eye Hospital/Chris Hani Baragwanath Academic Hospital, Chris Hani, FS, South Africa
Pretoria, GT, South Africa
Johannesburg South, GT, South Africa
Sandringham, GT 2131, South Africa
Durban, ZN, South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting
Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting
Enrollment Status: Completed
Publish Date: May 28, 2024
A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Biological
Study Drug: SARS-CoV-2 rS+Matrix-M1 Adjuvant
Study Phase: Phase 2
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged <=90 Days
Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged <=90 Days
Enrollment Status: Completed
Publish Date: September 13, 2018
View 4 Less Clinical Trials

643 Total Publications

Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Journal: The New England journal of medicine
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Madhi's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 17 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile